MA09 clinical trials
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How each study uses MA09 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- MA09-hRPE
- 5
Studies by the year they started
6 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 1 |
Who runs them
Industry 5 · Other 1
Astellas Institute for Regenerative Medicine (3) · CHABiotech CO., Ltd (2) · University of California, Los Angeles (1)
Studies
Open first, then newest update. How each study uses MA09 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular DystrophyCompletedPhase 1/2Astellas Institute for Regenerative MedicineNCT01345006Written as MA09-hRPE
- Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)CompletedPhase 1/2Astellas Institute for Regenerative MedicineNCT01469832Written as MA09-hRPE
- Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular DegenerationCompletedPhase 1/2Astellas Institute for Regenerative MedicineNCT01344993Written as MA09-hRPE
- Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD)CompletedPhase 1CHABiotech CO., LtdNCT01625559Written as MA09-hRPE
- A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry AMDTerminatedPhase 1/2CHABiotech CO., LtdNCT01674829Written as MA09-hRPE
- Research With Retinal Cells Derived From Stem Cells for Myopic Macular DegenerationWithdrawnPhase 1/2University of California, Los AngelesNCT02122159Written as MA09-hRPE Cellular Therapy